Zobrazeno 1 - 10
of 64
pro vyhledávání: '"Caroline Dutriaux"'
Autor:
Haocheng Li, Caroline Dutriaux, James Larkin, Edward McKenna, Claus Garbe, Luis de la Cruz-Merino, Athina Voulgari, Mario Mandalà, Paolo A. Ascierto, Lev V. Demidov, Victoria Atkinson, Brigitte Dréno, Antoni Ribas, Michele Maio, Gabriella Liszkay, Surai Jones, Luc Thomas, Jessie Hao-Ru Hsu, Grant A. McArthur, Daniil Stroyakovskiy
Publikováno v:
Clinical Cancer Research. 27:5225-5235
Purpose: The randomized phase III coBRIM study (NCT01689519) demonstrated improved progression-free survival (PFS) and overall survival (OS) with addition of cobimetinib to vemurafenib compared with vemurafenib in patients with previously untreated B
Autor:
Thierry Lesimple, Marc Pracht, Maxime Battistella, Matthieu Resche-Rigon, Caroline Dutriaux, Paul Vilquin, Annick Tibi, Zineb Ghrieb, Mona Amini-Adle, Barouyr Baroudjian, Coralie Reger de Moura, Samia Mourah, Samuel Huguet, Aurélie Sadoux, Baptiste Louveau, Didier Bouton, Céleste Lebbé, Julie Delyon, Fanélie Jouenne, Keyvan Rezai, Laetitia Da Meda
Publikováno v:
Clinical Cancer Research. 27:3876-3883
Purpose: In BRAFV600MUT metastatic melanoma, cyclin D–CDK4/6–INK4–Rb pathway alterations are involved in resistance to MAPK inhibitors, suggesting a clinical benefit of cyclin-dependent kinase 4 (CDK4) inhibitors. In this phase I–II study, we
Autor:
Gilles Poissonnet, Alexandra Picard-Gauci, Laurent Mortier, Julien Viotti, Julie De Quatrebarbes, Regis Kaphan, Maria Kogay, Henri Montaudié, Caroline Robert, Caroline Dutriaux, Anne-Bénédicte Duval-Modeste, Nicolas Dupin, Stéphane Dalle, Andrea Stefan, Patrick Combemale, Florence Brunet-Possenti, Frederic Peyrade
Publikováno v:
Oncotarget
There is no standard of care for unresectable cutaneous squamous cell carcinoma (cSCC). Chemotherapy, alone or combined with radiotherapy, is commonly used mostly as palliative treatment; moreover, its poor safety profile limits its use most of the t
Autor:
Emilie Gérard, Eric Alezra, Mokrane Yacoub, Caroline Dutriaux, Sorilla Prey, Sophie Schneider, Océane Ducharme
Publikováno v:
Melanoma research. 31(5)
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced melanoma. Combination of ICI with ipilimumab cytotoxic T-lymphocyte antigen-4 and nivolumab [anti-programmed cell death-1 (PD-1)] improves tumoral response compared to
Autor:
Mario Mandalà, Juliette Murris, Paola Queirolo, Ana Arance, Caroline Dutriaux, Helen Gogas, Gabriella Liszkay, Ralf Gutzmer, Claus Garbe, Keith T. Flaherty, Abir Tadmouri Sellier, Naoya Yamazaki, Jeanne Suissa, Ivana Krajsová, Vanna Chiarion Sileni, Caroline Robert, Reinhard Dummer, Groot Jan de Willem, Paolo A. Ascierto, Ashwin Gollerkeri, Carmen Loquai, Dirk Schadendorf
In COLUMBUS, treatment with encorafenib plus binimetinib in patients with advanced BRAF-mutant melanoma showed improved progression-free and overall survival with favourable tolerability compared to vemurafenib treatment. Here, results on health-rela
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00b598bc6b0d5210f8adf8a69fd7b47b
https://www.zora.uzh.ch/id/eprint/203982/
https://www.zora.uzh.ch/id/eprint/203982/
Autor:
Vanna Chiarion-Sileni, James Larkin, Richard F. Kefford, John M. Kirkwood, Mario Mandalà, Stephanie Manson, Kohinoor Dasgupta, Victoria Atkinson, Thierry Lesimple, Marta Nyakas, Reinhard Dummer, Axel Hauschild, Andrew Haydon, Laurent Mortier, Georgina V. Long, Dirk Schadendorf, Caroline Robert, Bijoyesh Mookerjee, Mario Santinami, Ruth Plummer, Caroline Dutriaux, Jacob Schachter, Roy Koruth
Publikováno v:
The Lancet Oncology. 20:701-710
Summary Background In the phase 3 COMBI-AD study, patients with resected, stage III melanoma with BRAF V600E or BRAF V600K mutations received adjuvant dabrafenib plus trametinib or placebo. The primary analysis showed that dabrafenib plus trametinib
Autor:
Keith T. Flaherty, Laure Moutouh-de Parseval, Michael D Pickard, Carmen Loquai, Victor Sandor, Naoya Yamazaki, Ivana Krajsová, Gabriella Liszkay, Reinhard Dummer, Dirk Schadendorf, Mario Mandalà, Ana Arance, Ralf Gutzmer, Claus Garbe, Paolo A. Ascierto, Helen Gogas, Caroline Robert, Jan Willem de Groot, Caroline Dutriaux, Vanna Chiarion Sileni
Publikováno v:
The Lancet Oncology. 19:1315-1327
Summary Background Encorafenib plus binimetinib and encorafenib alone improved progression-free survival compared with vemurafenib in patients with BRAF V600 -mutant melanoma in the COLUMBUS trial. Here, we report the results of the secondary endpoin
Autor:
Gaëlle Montes, Florian Poullenot, Fanny Duval, Caroline Dutriaux, Clémence Guerin, Guilhem Solé, Emilie Gérard, Séverine Amico, Cécile Herran, Céline Eldani, Louis Carla, Sorilla Prey, P. Celerier
Publikováno v:
Journal of immunotherapy (Hagerstown, Md. : 1997). 44(9)
Immunotherapy with immune checkpoint inhibitors (ICIs) has improved the prognosis of many cancers; a combination of nivolumab (anti-programmed cell death protein 1) and ipilimumab (anti-cytotoxic T-lymphocyte-associated protein 4) is approved as firs
Autor:
Sandrine Mansard, Philippe Saiag, Hervé Maillard, Amine Denden, Caroline Robert, Laurent Mortier, S. Dalac-Rat, Charlée Nardin, Olivier Dereure, Thierry Lesimple, Laurent Machet, Eve-Marie Neidhardt, Florent Grange, Alexandra Szenik, Caroline Dutriaux, Christophe Bedane, Céleste Lebbé, Jean-Jacques Grob
Publikováno v:
European Journal of Cancer
European Journal of Cancer, 2021, 154, pp.57-65. ⟨10.1016/j.ejca.2021.05.031⟩
European Journal of Cancer, Elsevier, 2021, 154, pp.57-65. ⟨10.1016/j.ejca.2021.05.031⟩
European Journal of Cancer, 2021, 154, pp.57-65. ⟨10.1016/j.ejca.2021.05.031⟩
European Journal of Cancer, Elsevier, 2021, 154, pp.57-65. ⟨10.1016/j.ejca.2021.05.031⟩
International audience; Background: BRAF and MEK inhibitors combination, including dabrafenib (D) and trametinib (T) have transformed the treatment of BRAF V600-mutant advanced melanoma patients, including patients with brain metastasis (BM). In a la
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7270e6beefeb71081cde6deee2aa0af2
https://hal.science/hal-03401780
https://hal.science/hal-03401780
Autor:
Anna Maria Di Giacomo, Georgina V. Long, Vanna Chiarion-Sileni, Helen Gogas, Micaela Hernberg, Kerry J. Savage, Laurent Mortier, Francesco Cognetti, Benjamin Brady, Cornelia Mauch, Caroline Robert, Julie Charles, Ana Arance, Piotr Rutkowski, Catriona M. McNeil, Lars Ny, Jesus Zoco, Ewa Kalinka, Sandra Re, Dirk Schadendorf, Victoria Atkinson, Caroline Dutriaux, Catalin Mihalcioiu, Paolo A. Ascierto, Jessica C. Hassel, Henrik Schmidt, Céleste Lebbé
Publikováno v:
Journal of Clinical Oncology
Robert, C, Long, G V, Brady, B, Dutriaux, C, Di Giacomo, A M, Mortier, L, Rutkowski, P, Hassel, J C, McNeil, C M, Kalinka, E A, Lebbé, C, Charles, J, Hernberg, M M, Savage, K J, Chiarion-Sileni, V, Mihalcioiu, C, Mauch, C, Arance, A, Cognetti, F, Ny, L, Schmidt, H, Schadendorf, D, Gogas, H, Zoco, J, Re, S, Ascierto, P A & Atkinson, V 2020, ' Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 38, no. 33, pp. 3937-3946 . https://doi.org/10.1200/JCO.20.00995
Robert, C, Long, G V, Brady, B, Dutriaux, C, Di Giacomo, A M, Mortier, L, Rutkowski, P, Hassel, J C, McNeil, C M, Kalinka, E A, Lebbé, C, Charles, J, Hernberg, M M, Savage, K J, Chiarion-Sileni, V, Mihalcioiu, C, Mauch, C, Arance, A, Cognetti, F, Ny, L, Schmidt, H, Schadendorf, D, Gogas, H, Zoco, J, Re, S, Ascierto, P A & Atkinson, V 2020, ' Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 38, no. 33, pp. 3937-3946 . https://doi.org/10.1200/JCO.20.00995
PURPOSE The CheckMate 066 trial investigated nivolumab monotherapy as first-line treatment for patients with previously untreated BRAF wild-type advanced melanoma. Five-year results are presented herein. PATIENTS AND METHODS In this multicenter, doub
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56e136a7f3cebfa513b285e44ed047f9
http://hdl.handle.net/10138/324446
http://hdl.handle.net/10138/324446